2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitorsCancer therapyInflammatory arthritisTherapyCancerArthritis
2022
Rheumatology (Arthritis and Myositis)
Kim S, Bowman S, Lu H. Rheumatology (Arthritis and Myositis). 2022, 301-313. DOI: 10.1007/978-3-031-00241-0_15.Peer-Reviewed Original ResearchImmune-related adverse eventsRheumatic immune-related adverse eventsImmune checkpoint inhibitorsAssociated with immune checkpoint inhibitorsDiscontinuation of immune checkpoint inhibitorsSystemic immune-related adverse eventsCourse of treatmentCheckpoint inhibitorsMyositis symptomsPersistent inflammatory arthritisComplete resolutionAdverse eventsRegistry studyInflammatory arthritisPrevalent typeMyositisPatientsArthritisArticularImmunosuppressionDMARDsArthralgiaMyalgiaPolymyalgiaDistinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.Peer-Reviewed Original ResearchConceptsCD8+ T cellsImmune-related adverse eventsImmune checkpoint inhibitorsT cellsCheckpoint inhibitorsAssociated with immune-related adverse eventsPD-1 inhibitor therapyT-cell axisEnhanced Th17Antitumor immunityCTLA-4PD-1Inhibitor therapyImmunomodulatory therapyTCR repertoirePredictive biomarkersPeripheral bloodMyeloid cellsAdverse eventsCell signaturesCancer therapyInflammatory arthritisInflamed jointsTherapyTherapeutic target
2021
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Kim S, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong D. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal For ImmunoTherapy Of Cancer 2021, 9: e002716. PMID: 34233963, PMCID: PMC8264871, DOI: 10.1136/jitc-2021-002716.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeT cellsCell therapyT-cell receptor T cellsTreatment of cytokine release syndromeImmune effector cell therapiesCalcium pyrophosphate dihydrate crystalsFallopian tube cancerT-cell therapyCD4<sup>+</sup> TDeposition of calcium pyrophosphate dihydrate crystalsTCR-T cellsEffector cell therapiesAmount of IL-6Left knee arthritisPresence of calcium pyrophosphate dihydrate crystalsMAGE-A4Th17 cellsNeurotoxicity syndromeCancer responseInterleukin-17IL-6TherapyInflammatory arthritis